Revenue segments as reported by the company.

Cardiovascular

Medical Surgical

Neuroscience

Diabetes

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Amortization of intangible assets

Restructuring charges, net

Certain litigation charges, net

Other operating expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Medtronic

Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiovascular Porrtfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment includes products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease. The Neuroscience Portfolio is made up of cranial and spinal technologies, specialty therapies, and neuromodulation divisions. The Medical Surgical Portfolio is comprised of surgical innovations and respiratory, gastrointestinal, and renal divisions. The Diabetes Group segment offers insulin pumps, continuous glucose monitoring systems, and insulin pump consumables. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Medtronic reports strong Q4 results, anticipates margin pressures for FY '24

MDT reported strong Q4 results with organic revenue growth, but anticipates margin pressures and EPS decline for FY '24. They highlighted successful FDA approvals and expressed confidence in growth opportunities.

Medtronic reports strong Q2 earnings, highlights growth opportunities

Medtronic's Q2 earnings call showcased strong financial performance, with raised full-year guidance. The company emphasized growth in key business segments and highlighted opportunities in insulin-dependent patient solutions and AI-powered solutions. Challenges include delays in PMRI spend and minimal impact of GLP-1s on the business.

Medtronic exceeds Q3 expectations, focuses on growth and transformation

Medtronic's Q3 earnings call highlighted strong performance, raised outlook, and a focus on transformation for sustainable growth. The company is strategically addressing challenges through cost reduction efforts and seizing opportunities in key markets. Medtronic remains committed to driving innovation and maximizing shareholder value.

Medtronic exceeds Q4 expectations, eyes growth in innovative healthcare

Medtronic's Q4 performance showcased strong growth in key segments, with a focus on innovation and market expansion. Despite challenges from inflation and currency impact, the company remains optimistic about future growth opportunities driven by product advancements and strategic acquisitions.

Medtronic reports robust Q1 results, eyes growth amid challenges

Medtronic's Q1 performance showcased strong revenue growth and emphasized innovation across key business segments.
While facing challenges of growth deceleration and margin expansion, the company remains focused on operational efficiencies and market fundamentals.
Opportunities lie in bariatric space growth, ongoing transformation efforts, and advancements in diabetes programs and surgical systems.
Overall, Medtronic's strategic investments in technology, pricing strategies, and procedural trends position it for continued success and market leadership.

Medtronic surpasses revenue expectations, eyes growth in key markets

Medtronic delivered strong Q2 results with revenue growth ahead of expectations and raised full-year guidance. Despite concerns about GLP-1 drugs and the SELECT trial, the company remains optimistic about growth prospects, focusing on key markets and product innovation.

Medtronic reports solid Q3 growth, focuses on innovation and profitability

Medtronic's Q3 earnings call showcased strong financial performance, international market growth, and strategic decisions to drive innovation and profitability. The company's focus on new technologies, portfolio management, and overcoming challenges highlights a path towards sustained growth and earnings leverage. With positive progress in key business segments and a commitment to future profitability, Medtronic is well-positioned for continued success.

Medtronic reports robust Q4 growth, eyes operational efficiency and China

Medtronic's Q4 2024 earnings call highlighted strong revenue growth, new product launches, and a focus on restoring earnings power. The company provided guidance for fiscal year '25, expecting organic revenue growth, operating margin expansion, and non-GAAP diluted EPS. Analyst questions centered on EPS guidance, revenue growth drivers, and operational efficiencies.

Medtronic reports solid Q1 results, raises guidance for fiscal '25

Medtronic's Q1 2025 performance reflects steady revenue growth and increased EPS, driven by strong performances in key business segments and global markets.
The company's focus on innovation, strategic partnerships, and diversified revenue streams positions it well for future growth and market expansion.
While challenges exist in maintaining growth momentum and navigating market complexities, Medtronic's raised guidance and growth expectations signal confidence in its ability to drive top-line growth and restore earnings power.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The company's newest Simplera™ CGM is 50% smaller than its previous generation with a simple insertion and improved user experience DUBLIN , Sept. 21, 2023 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced CE (Conformité Européenne) Mark approval for its new all-in-one, disposable Simplera™ continuous glucose monitor (CGM) featuring a simple, two-step insertion process.

Medtronic Diabetes announces CE Mark for new Simplera™ CGM with disposable all-in-one design

Intuitive Surgical

The artificial intelligence (AI) boom has taken the technology world by storm. However, this can benefit every sector and industry.

Why the market is excited about these two growth stocks?

CVS Health

Income-seeking investors with time before retirement should look for dividend stocks that can rapidly raise their payouts. Medtronic's dividend has risen 38% over the past five years, but its stock price has been beaten down.

2 Beaten-Down Dividend Growth Stocks That Look Like Bargains Now

Advanced Micro Devices

CRISPR Therapeutics

Moderna

Intellia Therapeutics

NVIDIA

Vertex Pharmaceuticals

Before investing in a trend, it's important to make sure it isn't a fad of the moment and instead has staying power. Artificial intelligence and CRISPR gene editing are two popular trends that could be game-changers down the road.

2 Top Trends to Invest $500 In Right Now

Novo Nordisk

Medtronic delivers a solid dividend as well as strong returns. CRISPR Therapeutics could soon have its first approved therapy on the market.

3 Top Healthcare Stocks Defying the Bear Market

Medical device giant Medtronic recently lifted its annual earnings guidance. CRISPR Therapeutics is heading for a major milestone: a regulatory decision on what may become its first product.

Better Bull Market Buy: CRISPR vs. Medtronic Stock

Medtronic plc (NYSE:MDT ) Bank of America Global Healthcare Conference Call September 13, 2023 10:55 AM ET Company Participants Geoff Martha - Chairman and Chief Executive Officer Conference Call Participants Travis Steed - Bank of America Merrill Lynch Travis Steed Good morning. I'm Travis Steed, the Bank of America U.S. medical device analyst, and we are happy to have Geoff Martha, CEO of Medtronic here this afternoon.

Medtronic plc (MDT) Bank of America Global Healthcare Conference (Transcript)

Danaher

Humana

Healthcare is a sector that has underperformed the broader stock market this year. The S&P 500 Health Care Sector Index is down over 2.50% year-to-date versus a 17% gain in the benchmark S&P 500 index.

The 3 Most Undervalued Healthcare Stocks to Buy in September 2023

Amgen

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

These 3 Health Care Stocks With Over 3% Dividend Yields Are Recommended By Wall Street's Most Accurate Analysts - CVS Health (NYSE:CVS), Amgen (NASDAQ:AMGN)

Apple

Bank of America

Disney

Alphabet

JPMorgan Chase & Co

Morgan Stanley

Microsoft

Pfizer

Seasonal tendencies for the U.S. stock market between now and the end of the year will favor large-cap stocks over small caps.

Why large-cap stocks are a better bet for the rest of 2023 — and 10 you want to own

BYD Company Limited

Coca-Cola

NextEra Energy

Finding the best stocks to buy can be tricky. In the stock market, this year has been a beacon for those with a glass-half-full perspective.

7 No-Brainer Stocks to Buy With $1000 Right Now

AbbVie

Bristol-Myers

Cardinal Health

Gilead Sciences

The strong move higher that Nvidia has driven in the stock market this year has been significant, and the world of artificial intelligence has driven stock prices this year.

Big Institutions Grab ‘Strong Buy' Dividend Stocks in a Sector Not Totally Driven by AI

Dell Technologies

Hasbro

Verizon

Walmart

TipRanks' analyst ranking service pinpoints Wall Street's best-performing stocks, including Dell and Verizon.

Top Wall Street analysts select these dividend stocks to enhance returns

Medical Properties Trust recently cut its dividend due to its financial problems. Medtronic's business is strong enough to handle economic issues, making its dividend secure.

This High-Yield Stock Is Cutting Its Dividend -- Here Is a Company That Won't

Amcor Plc

Franklin Resources

Colgate-Palmolive

Chevron

Essex Property Trust

Federal Realty Investment Trust

Realty Income Corp

Sysco

Target

T. Rowe Price Group

Walgreens

"Dividend Aristocrats in the S&P 500 Index have raised their annual payouts every year for at least 25 consecutive years." -- Kiplinger.com/Investing. 66 Aristocrats, screened as of September 1, 2023, represented all eleven Morningstar Sectors. Broker estimated-top-ten net-gains ranged 15.58%-45.47% topped-by WBA & NEE. By yield, WBA topped-all Aristocrats. Top-ten Yields from ESS, ABBV, TROW, FRT, BEN, IBM, AMCR, O, MMM, & WBA, averaged 4.99%.

Dividend Aristocrats: 4 Top Dogs Plus 6 Chasers For September

Medtronic plc (NYSE:MDT ) Wells Fargo 2023 Healthcare Conference August 6, 2023 12:00 PM ET Company Participants Geoff Martha - CEO Conference Call Participants Larry Biegelsen - Wells Fargo Larry Biegelsen All right. Good afternoon, everyone.

Medtronic plc (MDT) Wells Fargo 2023 Healthcare Conference (Transcript)

Dover

Hormel Foods

AI investing is hot and not contained in the tech world. While names like NVIDIA NASDAQ: NVDA garner much attention, numerous blue-chip names are already leaning into the AI action.

These 5 Dividend Aristocrats are Quality Stocks for AI Investing

Salesforce

GlaxoSmithKline

Thermo Fisher Scientific

Emulating the moves of hedge fund stock pickers, and some of the most successful hedge funds can produce sizable profits for retail investors. In fact, here are seven of the top institutional stock picks you may want to consider as we near the last few months of 2023.

7 Stocks Hedge Funds Are Loading Up On

Shares of Medtronic and CVS Health offer above-average dividend yields after falling significantly in recent weeks. One of CVS Health's integrated healthcare businesses recently experienced a setback, but its overall future still looks bright.

2 Underappreciated Dividend Stocks to Buy in September and Hold Forever

UnitedHealth Group

Healthcare stocks often make good long-term investments. After all, the U.S. healthcare industry is worth more than $700 billion annually and growing at a brisk clip, especially with an aging population and global health events such as the COVID-19 pandemic.

Market Crash Coming? 3 Healthcare Stocks to Buy for a Soft Landing.

Medtronic's revenue and profits advanced in its fiscal Q1. The company pays a dividend that is double that of the S&P 500 index.

Is Medtronic Stock a Buy for Income Investors?

News for Medtronic Stock (MDT)